Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

5509 - A Randomized Controlled, Open label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine versus Gemcitabine alone in Patients with Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment (NCT03126435)

Date

29 Sep 2019

Session

Poster Display session 2

Presenters

Li-Tzong Chen

Citation

Annals of Oncology (2019) 30 (suppl_5): v253-v324. 10.1093/annonc/mdz247

Authors

L. Chen1, E. Hitre2, W. Lee3, L. Bai4, Z. Papaï5, S.Y. KANG6, M. Dvorkin7, H.J. Choi8, S.C. Oh9, P. Artru10, J. Bachet11

Author affiliations

  • 1 National Health Research Institutes, National Institute of Cancer Research, 70456 - Tainan/TW
  • 2 Medical Oncology, National Institute of Oncology, Budapest/HU
  • 3 Center For Liver And Pancreatobiliary Cancer, National Cancer Center Goyang-si, 10200 - Gyeonggi-do/KR
  • 4 Department Of Internal Medicine, China Medical University Hospital, 404 - Taichung/TW
  • 5 Medical Oncology, Hungarian Defence Forces Military Hospital, Budapest/HU
  • 6 Hematology-oncology, Ajou University School of Medicine, 443-721 - Suwon/KR
  • 7 Department Of Oncology, BHI of Omsk Region Clinical Oncology Dispensary, Omsk/RU
  • 8 Division Of Medical Oncology, Department Of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 03722 - Seoul/KR
  • 9 Department Of Internal Medicine, Korea University Guro Hospital, Seoul/KR
  • 10 Gi Oncology, Hôpital privé Jean Mermoz, 69373 - Lyon/FR
  • 11 Hepatogastroenterology Department, Groupe Hospitalier Pitié Salpetriere, 75013 - Paris/FR
More

Resources

Abstract 5509

Background

Pancreatic cancer (PC) is the 4th deadliest cancer in Europe, with more than 95% of those affected dying from the disease and is set to be the second greatest cause of death from cancer by 2020.(ECPC, European Cancer Patient Coalition) FOLFIRINOX regimen is the standard 1st-line treatment for PC patients with good performance status; however, there is still no standard of care in 2nd-line therapy for patients failed FOLFIRINOX. EndoTAG-1 is a novel formulation of cationic liposomes embedded with Paclitaxel, which specifically displays antivascular and antiangiogenic activity. By binding and internalizing at tumor endothelial cells after intravenous administration, the cytostatic and cytotoxic activities of paclitaxel are targeted to the activated tumor endothelial cells.

Trial design

•Patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment will be screened and randomized into one of the two arms in the study (n = 218). •ArmA: EndoTAG-1 and Gemcitabine Patients will be administrated with EndoTAG-1 (22 mg/m²) twice weekly plus gemcitabine (1000 mg/m²) once weekly for 1 cycle (8 weeks), which consisting of 3 weeks of treatment and 1 week rest, followed by 3 weeks of treatment and 1 week rest. The treatment will be kept until any one of the following occurs: progressive disease or unacceptable toxicity or withdrawal of consent. •ArmB: Gemcitabine Patients will be administrated with Gemcitabine (1000 mg/m²) once weekly for 1 cycle (8 weeks), which consisting of 3 weeks of treatment and 1 week rest, followed by 3 weeks of treatment and 1 week rest. The treatment will be kept until any one of the following occurs: progressive disease or unacceptable toxicity or withdrawal of consent.

Clinical trial identification

NCT03126435, other study ID numbers:CT4006.

Editorial acknowledgement

Legal entity responsible for the study

SynCore Biotechnology Co., Ltd.

Funding

SynCore Biotechnology Co., Ltd.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings